Getinge (OM:GETI B): Assessing Valuation as Guidance Holds Firm Despite Tariffs and Currency Pressures

Getinge (OM:GETI B) reaffirmed its guidance for 2025, confirming expectations for 2% to 5% organic net sales growth and targeting over 12% earnings per share growth, even with ongoing headwinds from tariffs and currency shifts.

See our latest analysis for Getinge.

Backed by steady guidance and resilience in the face of tariffs and currency changes, Getinge’s shares have climbed with conviction this year, posting a robust 21.6% year-to-date share price return and an impressive 1-year total shareholder return of 21%. The recent momentum suggests investors are warming to Getinge’s consistent growth signals.

If Getinge’s trajectory has you thinking about other healthcare contenders, why not discover more opportunities with our handpicked healthcare stocks screener — See the full list for free.

But with shares rising and the company outperforming this year, should investors see Getinge as undervalued at current levels, or is the market already pricing in the company's ability to deliver on future growth?

Most Popular Narrative: 5.3% Undervalued

Getinge’s last close of SEK223.3 is below what the most-followed narrative considers fair value, spotlighting potential upside if optimistic projections play out. Investors are watching how operational changes and emerging healthcare trends might amplify Getinge’s long-term growth story.

Growing market adoption of technologically advanced products (for example, digital health solutions, connected devices, Paragonix organ transport systems, and the XEN disinfection portfolio) positions Getinge to benefit from increased digitalization and automation in hospitals. This should drive higher-margin software and service revenues, enhancing earnings quality and supporting margin expansion.

Read the complete narrative.

Think the future of digital healthcare is already priced in? The most popular narrative is betting on a major earnings shift and a profit margin expansion few see coming. Want to see what daring assumptions power this upbeat fair value? Dive deeper for the bullish logic and see if you agree with the consensus!

Result: Fair Value of SEK235.71 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing tariffs and rising regulatory hurdles could challenge Getinge’s margin expansion story. These factors may provide real tests for the bullish narrative ahead.

Find out about the key risks to this Getinge narrative.

Build Your Own Getinge Narrative

If you have a different take or you're keen to draw your own conclusions from the latest figures, you can craft a custom narrative in just a few minutes. Do it your way

A great starting point for your Getinge research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for More Smart Investment Ideas?

Don’t limit your research to just one stock. The right screener can help you spot hidden gems, high performers, and future leaders you might otherwise miss.

• Unlock the benefits of regular income by targeting rising payout opportunities with these 20 dividend stocks with yields > 3%, a tool designed to highlight stocks with robust dividend yields.
• Get ahead of the curve and follow emerging leaders in transformative technology by browsing these 27 AI penny stocks as they pioneer artificial intelligence breakthroughs.
• Capitalize on market mispricings by using these 843 undervalued stocks based on cash flows to seek out companies trading below their intrinsic value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com